Guerbet's GBCA agent Dotarem gains US FDA's OK for CNS MRIs
This article was originally published in Scrip
Executive Summary
Guerbet won the US FDA's approval on 20 March to market the French pharmaceutical firm's gadolinium-based contrast agent (GBCA) Dotarem (gadoterate meglumine) for use in magnetic resonance imaging (MRI) of the brain, spine and associated tissues in patients as young as 2 years.